| 3.06 -0.14 (-4.38%) | 04-29 11:15 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.08 |
1-year : | 4.77 |
| Resists | First : | 3.5 |
Second : | 4.08 |
| Pivot price | 3.15  |
|||
| Supports | First : | 3.03 |
Second : | 2.75 |
| MAs | MA(5) : | 3.09 |
MA(20) : | 3.1 |
| MA(100) : | 3.8 |
MA(250) : | 15.2 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 47.2 |
D(3) : | 44.6 |
| RSI | RSI(14): 47.2 |
|||
| 52-week | High : | 43.65 | Low : | 2.75 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TVRD ] has closed above bottom band by 50.0%. Bollinger Bands are 27.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.2 - 3.22 | 3.22 - 3.23 |
| Low: | 2.99 - 3 | 3 - 3.02 |
| Close: | 3.17 - 3.2 | 3.2 - 3.23 |
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).
Fri, 24 Apr 2026
TVRD Price Today: Tvardi Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Thu, 23 Apr 2026
Tvardi Therapeutics (NASDAQ: TVRD) outlines 2026 votes on board, pay and auditors - Stock Titan
Mon, 20 Apr 2026
MSN Money - MSN
Thu, 09 Apr 2026
Tvardi Therapeutics (TVRD) Price Target Decreased by 43.91% to 8.50 - MSN
Thu, 02 Apr 2026
Tvardi management heads to New York for Apr. 14 biotech symposium - Stock Titan
Thu, 02 Apr 2026
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 9 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 34.6 (%) |
| Held by Institutions | 30.1 (%) |
| Shares Short | 669 (K) |
| Shares Short P.Month | 637 (K) |
| EPS | -3.26 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.23 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -49.8 % |
| Return on Equity (ttm) | -237.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.85 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -24 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -0.97 |
| PEG Ratio | 0 |
| Price to Book value | 1.41 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|